Randomized Trialhigh evidence
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet (London, England)·August 23, 2025·PMID 40849139
Why it mattersThis is the first clinical evidence that DGAT2 inhibition can improve MASH histology, offering a novel mechanism independent of weight loss. It may complement GLP-1-based therapies and expands the therapeutic landscape for a condition with limited approved treatments.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled